

SAFETY DATA SHEET Cyclophosphamide for Injection, USP 500mg/vial

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Cyclophosphamide for Injection, USP 500mg/vial

Trade Name:	Cyclophosphamide for Injection, USP 500mg/vial
Chemical Family:	Alkylating Agent
Intended Use:	Pharmaceutical product used as Antineoplastic

Manufacturer Name and Address

Amneal Oncology Pvt. Ltd. TSIIC-SEZ, Plot No. S-3, S-4, S-5A, Polepally (Vil), Jadcherla (Mdl), Mahaboobnagar (Dist); Telangana, India, Pin - 509301 Emergency Telephone number : +91-8542-302000

2. HAZARDS IDENTIFICATION

Appearance: Signal Word:	WhitePowder DANGER		
Statement of Hazard:	Toxic if swallowed. May cause cancer. May damage fertility or the unborn child. May cause genetic defects.		
Additional Hazard Information: Long Term:	The use of this drug during pregnancy has resulted in birth defects. Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system.		
Known Clinical Effects:	Effects on blood and blood-forming organs have also occurred.		
EU Classification EU Indication of danger:	Toxic Toxic to reproduction Carcinogenic Mutagenic	: Category 1 : Category 1 : Category 1	

EU Hazard Symbols:



EU Risk Phrases:

R25 - Toxic if swallowed.

- R45 May cause cancer.
- R46 May cause heritable genetic damage.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.



SAFETY DATA SHEET Cyclophosphamide for Injection, USP 500mg/vial

Australian Hazard Classification (NOHSC): Hazardous Substance. Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	Qty / Unit	% W/W
Cyclophosphamide Monohydrate	50-18-0	200-015-4	T;R25 Repr.Cat.1;R60-61 Carc. Cat.1;R45 Mut. Cat.1;R46	534.5 mg	100

Additional Information:

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES		
Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.	
Skin Contact: Seek	Remove contaminated clothing. Flush area with large amounts of water. Use soap.	
	medical attention.	
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.	
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.	
Symptoms and Effects of Expo	sure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.	
5. FIRE FIGHTING MEASURE	-S	

5. FIRE FIGHTING MEASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Product	s: Carbon dioxide, carbon monoxide, and oxides of nitrogen phosphorous
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.



SAFETY DATA SHEET

Cyclophosphamide for Injection, USP 500mg/vial

Health and Safety Precautions:	Personnel involved in cle	an-up should wear appropr	iate personal protective equipmer
······	(See Section 8). Minimiz		
Measures for Cleaning /			
Collecting:			ect spilled material by a method
		tion. A damp cloth or a filte Clean spill area thoroughly	red vacuum should be used to /.
Measures for	Place waste in an approp	riately labeled, sealed cont	ainer for disposal. Care should b
Environmental	taken to avoid environme	ental release.	
Protections:			
Additional Consideration for		should be evacuated from a	
Large Spills:		mediately. Clean up operat	tions should only be undertaken
	by trained personnel.		
7. HANDLING AND STORAGE			
General Handling:		rea. Designate a change ar	
		ination practices. Ground a	
			ons should be fully enclosed.
		act with skin, eye, and clot	u
			tion 8). Wash hands and any
	•		environment should be avoided. Decedural waste water and waste
			e or environmental releases.
			I to the atmosphere should be
			ms or other equivalent controls.
Storage Conditions:			liners. Keep away from heat,
-	sparks and flames.		
8. EXPOSURE CONTROLS / P	ERSONAL PROTECTIO	N	
No Occupational Exposure Limit			
Engineering Controls:			means to control exposures. Use
			ther engineering controls to sure limits. All operations should
	be fully enclosed. No air		sure limits. All operations should
Environmental Exposure Control			rements under Community
	Environmental legislation	1.	
Personal Protective Equipment:			ns in the selection and use of
	Personal Protective Equi	oment (PPE).	
Hands:	Wear impervious, dispos	able gloves as minimum pro	otection (double recommended).
Eyes:	Wear safety glasses as r		
Skin:		ble protective clothing whe	
Respiratory protection:	Whenever excessive air	contamination (dust, mist, v	apor) is generated, respiratory
	exposure.	ate protection factors, shou	ia de usea to minimize
9. PHYSICAL AND CHEMICAL	PROPERTIES		
Physical State:	Powder	Color:	White

Physical State:	Powder	Color:	White
Molecular Formula:	C7 H15 Cl2 N2 O2 P	Molecular Weight:	261.09
Water solubility:	4%		



SAFETY DATA SHEET

Cyclophosphamide for Injection, USP 500mg/vial

9. PHYSICAL AND CHEMICAL PROPERTIES

Melting/Freezing Point (°C): 41

10. STABILITY AND REACTIVITY

Chemical Stability:	Stable under normal conditions of use.
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Cyclophosphamide

RatOralLD 50160 mg/kgRatPara-periostealLD 50148 mg/kgMouseOralLD 50137 mg/kgMouseIntravenousLD 50140 mg/kg

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Cyclophosphamide

Embryo / Fetal Development	Rat	Intraperitoneal	10 mg/kg	LOAEL	Teratogenic
Embryo / Fetal Development	Rat	Intraperitoneal	30 mg/kg	LOAEL	Fetotoxicity
Embryo / Fetal Development	Mouse	Intravenous	10 mg/kg	LOAEL	Teratogenic
Embryo / Fetal Development	Mouse	Intraperitoneal	5 mg/kg	LOAEL	Fetotoxicity, Fertility

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cyclophosphamide

In Vivo MicronucleusRodentPositiveIn Vivo Chromosome AberrationRodentPositiveIn Vivo Sister Chromatid ExchangeRodentPositiveIn Vitro Chromosome AberrationHuman LymphocytesPositiveDominant Lethal AssayDrosophilaPositive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Cyclophosphamide

2 Year(s) Rat Intravenous Benign tumors, Malignant tumors
2 Year(s) Rat Intraperitoneal Benign tumors, Malignant tumors, Female reproductive system
2 Year(s) Mouse Intraperitoneal Benign tumors, Malignant tumors

Carcinogen Status: See below

Cyclophosphamide

IARC:	Group 1 (Carcinogenic to Humans)
NTP:	Known Human Carcinogen
OSHA:	Listed



SAFETY DATA SHEET Cyclophosphamide for Injection, USP 500mg/vial

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Cyclophosphamide

RCRA - U Series Wastes

Listed

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number:	UN 2811
UN proper shipping name:	Toxic solid, organic, n.o.s. (cyclophosphamide)
Transport hazard class(es):	6.1
Packing group:	III

15. REGULATORY INFORMATION

EU Symbol: EU Indication of danger:	T Toxic Toxic to reproduction: Category 1 Carcinogenic: Category 1 Mutagenic: Category 1
EU Risk Phrases:	R25 - Toxic if swallowed. R45 - May cause cancer. R46 - May cause heritable genetic damage. R60 - May impair fertility. R61 - May cause harm to the unborn child.
EU Safety Phrases:	S22 - Do not breathe dust.S53 - Avoid exposure - obtain special instructions before use.S36/37 - Wear suitable protective clothing and gloves.



SAFETY DATA SHEET

Cyclophosphamide for Injection, USP 500mg/vial

OSHA Label:

DANGER Toxic if swallowed. May cause cancer. May damage fertility or the unborn child. May cause genetic defects.

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

R25 - Toxic if swallowed.

R45 - May cause cancer.

R46 - May cause heritable genetic damage.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

MSDS Origination Date: May 16, 2018 **Version #:** 00

Disclaimer:

The information above is provided in good faith. It is believed to be accurate and represents the best information currently available to us. HOWEVER, WE MAKE NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER TYPE, EXPRESSED OR IMPLIED, WITH RESPECT TO PRODUCTS DESCRIBED OR DATA OR INFORMATION PROVIDED, AND WE ASSUME NO LIABILITY RESULTING FROM THE USE OF SUCH PRODUCTS, DATA OR INFORMATION. Users should make their own investigations to determine the suitability of the information for their particular purposes, and the user assumes all risk arising from their use of the material. The user is required to comply with all laws and regulations relating to the purchase, use, storage and disposal of the material, and must be familiar with and follow generally accepted safe handling procedures. In no event shall Amneal be liable for any claims, losses, or damages of any individual or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if Amneal has been advised of the possibility of such damages.